Petros Pharmaceuticals, INC 8-K filings

Petros Pharmaceuticals reports mutual separation with VP of Finance Mitchell Arnold and appoints Robert Weinstein as Chief Accounting Officer.

Petros Pharmaceuticals, Inc. announced the grant of 7,000,000 restricted common stock shares to key directors and officers.

Petros Pharmaceuticals, Inc. announced the grant of 7,250,000 restricted stock units to its Chairman, President, and two directors, with immediate and six-month vesting.

Petros Pharmaceuticals, Inc. received notice from Nasdaq regarding the delisting of its common stock, which will continue trading on the OTCID Basic Market.

Petros Pharmaceuticals, Inc. announced the dismissal of CBIZ CPAs P.C. and the appointment of HTL International, LLC as its new independent registered public accounting firm, effective August 29, 2025.

Petros Pharmaceuticals, Inc. announced the termination of its Stendra license agreement and the assignment of its Metuchen, Timm Medical, and Pos-T-Vac subsidiaries' assets for the benefit of creditors, leading to a significant restructuring and pro forma stockholders' equity of approximately $8.0 million.

Petros Pharmaceuticals, Inc. received notice from Nasdaq that its securities will be delisted due to non-compliance with listing rules and public interest concerns.

Petros Pharmaceuticals implements a 1-for-25 reverse stock split and is addressing Nasdaq's concerns regarding a recent public offering to avoid delisting.

Petros Pharmaceuticals is appealing a Nasdaq delisting notice due to non-compliance with minimum stockholders' equity and has received stockholder approval for increasing authorized shares and amending its incentive plan.

Petros Pharmaceuticals terminates its relationship with Marcum LLP and engages CBIZ CPAs as its independent registered public accounting firm, effective April 5, 2025.

Petros Pharmaceuticals announces the pricing of a $9.6 million public offering involving common stock and warrants to fund working capital and general corporate purposes.

Petros Pharmaceuticals amends its agreement with investors to extend the maturity date of its Series A Convertible Preferred Stock and modify certain covenants.

Petros Pharmaceuticals' subsidiary, Metuchen Pharmaceuticals, defaulted on a loan, leading to the acceleration of $7.5 million in debt and a partial foreclosure of collateral.

Petros Pharmaceuticals successfully held its 2024 annual meeting, approving the election of directors, ratification of auditors, executive compensation, a reverse stock split, and a proposal to adjourn the meeting if necessary.

Petros Pharmaceuticals has amended its employment agreement with President and Chief Commercial Officer Fady Boctor, reducing his base salary and allowing outside consulting work.

Petros Pharmaceuticals has amended the voting rights of its Series A Convertible Preferred Stock, granting holders the right to vote with common stockholders on an as-converted basis.

Petros Pharmaceuticals reports the resignation of two board members, John Shulman and Greg Bradley, effective October 1st and 2nd, 2024, respectively.

Petros Pharmaceuticals has announced the date for its 2024 Annual Meeting of Stockholders and established deadlines for shareholder proposals and director nominations.

Petros Pharmaceuticals has amended its agreement with investors to clarify that certain equity awards granted to directors, officers, and employees are excluded from previous transaction restrictions.

Petros Pharmaceuticals has dismissed EisnerAmper LLP and appointed Marcum LLP as its new independent registered public accounting firm, effective January 8, 2024.